Pharmacokinetics and Safety Profile of the Human Anti- Pseudomonas aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy Volunteers
Open Access
- 1 August 2009
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (8), 3442-3446
- https://doi.org/10.1128/aac.01699-08
Abstract
KBPA-101 is a human monoclonal antibody of the immunoglobulin M isotype, which is directed against the O-polysaccharide moiety of Pseudomonas aeruginosa serotype O11. This double-blind, dose escalation study evaluated the safety and pharmacokinetics of KBPA-101 in 32 healthy volunteers aged 19 to 46 years. Each subject received a single intravenous infusion of KBPA-101 at a dose of 0.1, 0.4, 1.2, or 4 mg/kg of body weight or placebo infused over 2 h. Plasma samples for pharmacokinetic assessments were taken before infusion as well as 0.25, 0.5, 1, 2, 2.5, 4, 6, 8, 12, 24, 36, and 48 h and 4, 7, 10, and 14 days after start of dosing. Plasma concentrations of KBPA-101 were detected with mean maximum concentrations of drug in plasma of 1,877, 7,571, 24,923, and 83,197 ng/ml following doses of 0.1, 0.4, 1.2, and 4.0 mg/kg body weight, respectively. The mean elimination half-life was between 70 and 95 h. The mean volume of distribution was between 4.76 and 5.47 liters. Clearance ranged between 0.039 and 0.120 liters/h. At the highest dose of 4.0 mg/kg, plasma KBPA-101 levels were greater than 5,000 ng/ml for 14 days. KBPA-101 exhibited linear kinetics across all doses. No anti-KBPA-101 antibodies were detected after dosing in any subject. Overall, the human monoclonal antibody KBPA-101 was well tolerated over the entire dose range in healthy volunteers, and no serious adverse events have been reported.This publication has 18 references indexed in Scilit:
- Immunogenicity of protein therapeuticsTrends in Immunology, 2007
- Use of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa InfectionsClinical Infectious Diseases, 2005
- Antibody Pharmacokinetics and PharmacodynamicsJournal of Pharmaceutical Sciences, 2004
- National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003American Journal of Infection Control, 2003
- Infection Control in the ICUSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2001
- Characterization ofPseudomonas aeruginosaIsolates: Occurrence Rates, Antimicrobial Susceptibility Patterns, and Molecular Typing in the Global SENTRY Antimicrobial Surveillance Program, 1997–1999Clinical Infectious Diseases, 2001
- Pharmacokinetics, Tolerability, and Preliminary Efficacy of Human Anti-Pseudomonas aeruginosaMonoclonal Antibodies in Pneumonia and Burn Infection PatientsHybridoma, 1997
- Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosisThe Journal of Pediatrics, 1995
- Biological Role of Different Antibody ClassesInternational Archives of Allergy and Immunology, 1989
- The Virulence of Pseudomonas aeruginosaClinical Infectious Diseases, 1984